TB Alternative Assets Ltd. has joined the biotech investing party by purchasing 3,158 shares of Regeneron Pharmaceuticals ...

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

Atwood & Palmer Inc. slightly reduced its stake in Regeneron Pharmaceuticals, selling 1,709 shares in Q1 while still holding ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results ...

For more comprehensive information about current price movements while Regeneron shares crash, please visit CDS.

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

US biotech Regeneron and French drugmaker Sanofi are reviewing next steps for their experimental COPD therapy itepekimab ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 ...